Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.56 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226723 | 1.00 | USP30 (0.56) | USP30GRM5HSD11B1HPGDSGPR119 | |
| SCHEMBL4226659 | 0.86 | HSD11B1 (0.62) | USP30HSD11B1HPGDSGPR119PRMT5 | |
| SCHEMBL4227292 | 0.85 | USP30 (0.49) | USP30HSD11B1HPGDSGPR119PRMT5 | |
| SCHEMBL4227295 | 0.85 | USP30 (0.49) | USP30HSD11B1HPGDSGPR119PRMT5 | |
| SCHEMBL4221520 | 0.83 | USP30 (0.58) | USP30HSD11B1HPGDSGPR119HDAC4 | |
| SCHEMBL193071 | 0.83 | GRM5 (0.69) | GRM5HSD11B1 | |
| SCHEMBL193072 | 0.83 | GRM5 (0.69) | GRM5HSD11B1 | |
| SCHEMBL4226960 | 0.83 | USP30 (0.52) | USP30HSD11B1HPGDSHDAC4HDAC6 | |
| SCHEMBL4223109 | 0.83 | USP30 (0.52) | USP30HSD11B1HPGDSGPR119PRMT5 | |
| SCHEMBL1970111 | 0.81 | USP30 (0.50) | USP30HSD11B1HPGDSGPR119PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NIKEM RESEARCH SRL (IT) | 2009-08-27 | — | — | US | disclosed |
| EP-1893606-A2 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006123255-A2 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM3, GRM2 | USP30 1767/4885GRM5 1/4885HSD11B1 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.